Montara Therapeutics Secures $1M Michael J. Fox Foundation Grant for Parkinson's Disease Research

San Francisco-based Montara Therapeutics has secured an approximately $1M non-dilutive research grant from The Michael J. Fox Foundation (MJFF) to advance its BrainOnly™ platform for Parkinson's disease research. The funding will support development of brain-selective approaches targeting the mTOR pathway, with the goal of activating autophagy in the brain while minimizing systemic side effects.

The grant marks Montara Therapeutics' second award from The Michael J. Fox Foundation. In 2025, MJFF awarded the company $3.3M to advance its BrainOnly™ LRRK2 inhibitor program, bringing total non-dilutive funding from the foundation to approximately $4.3M.

The significance extends beyond the dollar amount. Parkinson's disease remains one of the most difficult challenges in medicine, and repeat support from one of the world's most influential Parkinson's research organizations signals growing confidence in both the science and the team behind Montara Therapeutics.

The broader implication is equally important. As drug developers search for ways to improve both efficacy and safety, brain-selective therapeutic platforms are emerging as a critical area of innovation across neurodegenerative disease research.

What Happened

Montara Therapeutics announced that The Michael J. Fox Foundation awarded the company an approximately $1M grant through its Therapeutics Pipeline Program to support BrainOnly™ research targeting the mTOR pathway in Parkinson's disease. The company plans to evaluate clinically utilized mTOR inhibitors in combination with MT1110, Montara Therapeutics' peripheral blocker, to activate autophagy in the brain while reducing activity outside the central nervous system. Researchers will study whether this approach can help clear alpha-synuclein, a protein widely associated with Parkinson's disease pathology and progression.

For a disease area where scientific progress is measured in years rather than quarters, repeat support from The Michael J. Fox Foundation carries substantial weight. Organizations like MJFF do not allocate funding based on enthusiasm alone. They invest in scientific rationale, evidence generation, and the potential to advance the Parkinson's disease therapeutic landscape. Montara Therapeutics has now earned that endorsement twice.

Why This Matters

The history of central nervous system (CNS) diseases drug development is filled with therapies that demonstrated promise in the brain but struggled because of unwanted effects elsewhere in the body. The challenge is rarely identifying a compelling biological target. The challenge is controlling where a therapy works. Many neurological treatments interact with pathways that exist throughout the body, meaning a drug may effectively engage its intended target in the brain while simultaneously triggering unintended consequences in peripheral tissues. That dynamic has limited dosing, reduced tolerability, and contributed to the failure of numerous otherwise promising programs.

Montara Therapeutics believes BrainOnly™ offers a solution. The company's BrainOnly™ platform uses a binary pharmacology strategy designed to concentrate therapeutic activity in the brain while limiting activity outside the central nervous system. If successful, BrainOnly™ could unlock therapeutic opportunities that have historically been constrained by safety concerns rather than biological efficacy. In biotechnology, the difference between a breakthrough and a setback is often measured by side effects.

The Team Behind Montara Therapeutics

Founder, President, and CEO Nicholas T. Hertz, Ph.D. brings a track record that immediately stands out to both investors and scientific collaborators. Before launching Montara Therapeutics, Nicholas T. Hertz co-founded Mitokinin alongside Kevan M. Shokat, Ph.D.. Mitokinin was acquired by AbbVie in 2023 in a transaction valued at up to $655M.

Montara Therapeutics was founded alongside a scientific team that includes Kevan M. Shokat, Ph.D., Thomas C. Südhof, M.D., and Martin Kampmann, Ph.D.. That roster spans neuroscience, chemistry, genomics, neurodegeneration, and drug discovery. In biotechnology, scientific credibility is not simply a résumé item. It is often one of the company's most valuable assets.

The combination of experienced operators, accomplished researchers, and a platform-oriented strategy helps explain why both investors and disease-focused organizations continue supporting the company's work.

Market Context

The central nervous system therapeutics market remains one of the most attractive and challenging areas in biotechnology. Investors continue funding CNS-focused companies because the unmet need remains enormous across Parkinson's disease, Alzheimer's disease, epilepsy, and related neurological disorders. Yet the scientific and regulatory hurdles remain notoriously high.

Many companies spend years validating targets only to discover that efficacy alone is not enough. Safety, tolerability, and dosing limitations often determine whether a therapy advances or stalls. Montara Therapeutics is positioning BrainOnly™ as a platform designed to address that challenge.

Rather than pursuing a single therapeutic asset, the company is building a framework that could potentially be applied across multiple CNS programs. Parkinson's disease research increasingly serves as a proving ground for technologies that may later expand into Alzheimer's disease and other neurodegenerative disorders. That makes the implications broader than a single grant announcement.

What This Signals

The most important takeaway is not the size of the grant. A $1M award will not reshape biotechnology financing markets. The signal is what matters. Montara Therapeutics has raised $28M in seed financing from investors including SV Health Investors' Dementia Discovery Fund, Two Bear Capital, Dolby Family Ventures, KdT Ventures, and BEVC, while also securing approximately $4.3M in non-dilutive funding from The Michael J. Fox Foundation.

Investors and research organizations are independently arriving at a similar conclusion: brain-selective drug development deserves deeper exploration. When institutional investors and mission-driven foundations continue validating the same platform, sophisticated operators pay attention. Not because success is guaranteed, but because repeated validation is difficult to manufacture.

The Bigger Industry Shift

For years, much of biotechnology focused on discovering new biological targets. Today, an increasing number of companies are concentrating on a different challenge: how to engage known biology more safely and more precisely. That shift reflects a broader industry reality, as many future therapeutic advances may come not from finding entirely new targets but from developing better ways to reach targets researchers already understand.

Montara Therapeutics represents part of that movement. The company's BrainOnly™ platform is ultimately a bet that precision of activity can be just as important as potency of activity. Continued support from The Michael J. Fox Foundation suggests that thesis is gaining attention among researchers, investors, and disease-focused organizations alike, while the next chapter will depend on whether that scientific promise can translate into clinical outcomes.